← All indications
Neurofibroma, Plexiform
A type of neurofibroma manifesting as a diffuse overgrowth of subcutaneous tissue, usually involving the face, scalp, neck, and chest but occasionally occurring in the abdomen or pelvis. The tumors tend to progress, and may extend along nerve roots to eventually involve the spinal roots and spinal cord. This process is almost always a manifestation of NEUROFIBROMATOSIS 1. (From Adams et al., Principles of Neurology, 6th ed, p1016; J Pediatr 1997 Nov;131(5):678-82)
Drugs by status
Organizations
Organization Involved with Phase 2 Indications (29)
- AstraZeneca
- Pfizer
- Novartis
- Array BioPharma
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- Region Skane
- University of Pennsylvania
- University of Pittsburgh
- University of London
- Harvard University
- Indiana University
- Lund University
- McGill University
- Mayo Clinic
- Laval University
- University of Chicago
- University of Cincinnati
- University of Utah
- Food and Drug Administration
- Department of Defense
- University of Montreal
- University of Alabama, Birmingham
- University of Paris
- Washington University in St. Louis
- Children's National Medical Center
- The Pacific Pediatric Neuro-Oncology Consortium
- St. Justine's Hospital
- SpringWorks Therapeutics, Inc.
Organization Involved with Phase 1 Indications (4)